| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,946,331 | 1 | 2 |
Sells | $4,466,078 | 40 | 98 |
| MOTT DAVID M | director | 1 | $1.95M | 0 | $0 | $1.95M |
| Hohenleitner Susan | Chief Financial Officer | 0 | $0 | 3 | $27,014 | $-27,014 |
| GRAMMER ELIZABETH A | See Remarks | 0 | $0 | 1 | $33,194 | $-33,194 |
| Brady James Parker | Chief Human Resources Officer | 0 | $0 | 3 | $84,816 | $-84,816 |
| Bishop John E | See Remarks | 0 | $0 | 3 | $109,213 | $-109,213 |
| Reilly Joseph James | See Remarks | 0 | $0 | 4 | $129,230 | $-129,230 |
| Kelliher Mike | See Remarks | 0 | $0 | 4 | $162,233 | $-162,233 |
| Foster Eric Duane | Chief Commercial Officer | 0 | $0 | 4 | $176,376 | $-176,376 |
| Williams Laura A | Chief Patient Officer | 0 | $0 | 7 | $1.03M | $-1.03M |
| RAAB MICHAEL | President & CEO | 0 | $0 | 11 | $2.72M | $-2.72M |
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage …
Over the last 12 months, insiders at Ardelyx, Inc. have bought $1.95M and sold $4.47M worth of Ardelyx, Inc. stock.
On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $2.43M and sold $5.88M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MOTT DAVID M (director) — $1.95M.
The last purchase of 333,333 shares for transaction amount of $1.95M was made by MOTT DAVID M (director) on 2026‑02‑20.
| 2026-08-21 | Sale | RAAB MICHAEL | President & CEO | 58,574 0.0234% | $3.86 | $225,914 | -12.85% | |
| 2026-08-21 | Sale | Foster Eric Duane | Chief Commercial Officer | 8,562 0.0034% | $3.86 | $33,023 | -12.85% | |
| 2026-08-21 | Sale | Williams Laura A | Chief Patient Officer | 10,739 0.0043% | $3.86 | $41,419 | -12.85% | |
| 2026-08-21 | Sale | Kelliher Mike | Chief Business Officer | 7,758 0.0031% | $3.86 | $29,922 | -12.85% | |
| 2026-08-21 | Sale | Bishop John E | See Remarks | 19,750 0.0079% | $3.86 | $76,174 | -12.85% | |
| 2026-08-21 | Sale | Brady James Parker | Chief Human Resources Officer | 15,136 0.006% | $3.86 | $58,378 | -12.85% | |
| 2026-08-21 | Sale | Hohenleitner Susan | Chief Financial Officer | 1,558 0.0006% | $3.86 | $6,009 | -12.85% | |
| 2026-08-21 | Sale | Reilly Joseph James | See Remarks | 3,982 0.0016% | $3.86 | $15,358 | -12.85% | |
| 2026-07-15 | Sale | RAAB MICHAEL | President & CEO | 41,668 0.0161% | $5.06 | $210,923 | -30.85% | |
| 2026-06-18 | Sale | Williams Laura A | Chief Patient Officer | 81,898 0.0328% | $5.99 | $490,487 | -37.19% | |
| 2026-06-15 | Sale | RAAB MICHAEL | President & CEO | 41,666 0.0168% | $5.67 | $236,346 | -32.95% | |
| 2026-05-21 | Sale | RAAB MICHAEL | President & CEO | 22,794 0.0091% | $6.27 | $142,861 | -37.24% | |
| 2026-05-21 | Sale | RAAB MICHAEL | President & CEO | 54,748 0.0219% | $6.27 | $343,133 | -37.24% | |
| 2026-05-21 | Sale | Williams Laura A | Chief Patient Officer | 6,989 0.0028% | $6.27 | $43,804 | -37.24% | |
| 2026-05-21 | Sale | Williams Laura A | Chief Patient Officer | 3,329 0.0013% | $6.27 | $20,865 | -37.24% | |
| 2026-05-21 | Sale | Foster Eric Duane | Chief Commercial Officer | 7,998 0.0032% | $6.27 | $50,127 | -37.24% | |
| 2026-05-21 | Sale | Kelliher Mike | Chief Business Officer | 7,248 0.0029% | $6.27 | $45,427 | -37.24% | |
| 2026-05-21 | Sale | Bishop John E | See Remarks | 2,306 0.0009% | $6.27 | $14,453 | -37.24% | |
| 2026-05-21 | Sale | Brady James Parker | Chief Human Resources Officer | 1,846 0.0007% | $6.27 | $11,570 | -37.24% | |
| 2026-05-21 | Sale | Hohenleitner Susan | Chief Financial Officer | 1,455 0.0006% | $6.27 | $9,119 | -37.24% |
| MOTT DAVID M | director | 3302918 1.3255% | $10.01M | 17 | 0 | +26.64% |
| RAAB MICHAEL | President & CEO | 1619792 0.65% | $4.91M | 1 | 71 | +248.1% |
| Williams Laura A | Chief Patient Officer | 367456 0.1475% | $1.11M | 1 | 25 | +248.1% |
| GRAMMER ELIZABETH A | See Remarks | 299895 0.1203% | $908,681.85 | 2 | 44 | +117.06% |
| BARRIS PETER J | 10 percent owner | 8752543 3.5124% | $26.52M | 3 | 1 | +14.45% |
| BARRETT M JAMES | 10 percent owner | 8752543 3.5124% | $26.52M | 3 | 1 | +14.45% |
| KERINS PATRICK J | 10 percent owner | 8752543 3.5124% | $26.52M | 3 | 0 | +14.45% |
| KOLLURI KRISHNA KITTU | 10 percent owner | 8752543 3.5124% | $26.52M | 3 | 1 | +14.45% |
| New Enterprise Associates 12, Limited Partnership | 10 percent owner | 8752543 3.5124% | $26.52M | 4 | 0 | +10.87% |
| DRANT RYAN D | 10 percent owner | 7488893 3.0053% | $22.69M | 1 | 0 | +13.19% |
| MAKOWER JOSHUA | 10 percent owner | 2665520 1.0697% | $8.08M | 2 | 0 | +15.09% |
| Weller Harry R | 10 percent owner | 2665520 1.0697% | $8.08M | 2 | 0 | +15.09% |
| Viswanathan Ravi | 10 percent owner | 2665520 1.0697% | $8.08M | 2 | 0 | +15.09% |
| Sonsini Peter W. | 10 percent owner | 2665520 1.0697% | $8.08M | 2 | 0 | +15.09% |
| Florence Anthony A. Jr. | 10 percent owner | 2665520 1.0697% | $8.08M | 2 | 0 | +15.09% |
| Sakoda Jon | 10 percent owner | 2665520 1.0697% | $8.08M | 2 | 0 | +15.09% |
| NEA 15 GP, LLC | 10 percent owner | 2665520 1.0697% | $8.08M | 2 | 0 | +15.09% |
| SANDELL SCOTT D | 10 percent owner | 2258850 0.9065% | $6.84M | 3 | 8 | +14.45% |
| BASKETT FOREST | 10 percent owner | 2258850 0.9065% | $6.84M | 3 | 8 | +14.45% |
| SCHULTZ PETER G | director | 907429 0.3642% | $2.75M | 1 | 0 | +13.19% |
| Renz Justin A | Chief Financial Officer | 409052 0.1642% | $1.24M | 1 | 22 | +248.1% |
| Rosenbaum David P. | Chief Development Officer | 151373 0.0607% | $458,660.19 | 1 | 55 | +248.1% |
| Felsch Robert Ora | See Remarks | 91560 0.0367% | $277,426.80 | 1 | 8 | +248.1% |
| CMEA Ventures VII LP | 10 percent owner | 80990 0.0325% | $245,399.70 | 1 | 2 | +0.13% |
| RINGOLD GORDON | director | 25000 0.01% | $75,750.00 | 3 | 0 | +13.84% |
| Bertrand William C JR | director | 5000 0.002% | $15,150.00 | 1 | 0 | <0.0001% |
$100,473,344 | 83 | 9.53% | $826.91M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
Ardelyx, Inc. (ARDX) | $1,108,102,085 | 66 | 36.91% | $755.04M |
$59,156,363 | 22 | 29.25% | $686.5M | |
$22,365,077 | 19 | -27.47% | $674.89M |
| Increased Positions | 120 | +47.62% | 31M | +19.19% |
| Decreased Positions | 111 | -44.05% | 25M | -15.71% |
| New Positions | 39 | New | 14M | New |
| Sold Out Positions | 26 | Sold Out | 13M | Sold Out |
| Total Postitions | 261 | +3.57% | 167M | +3.48% |
| Blackrock, Inc. | $128,065.00 | 8.57% | 20.82M | +75,727 | +0.36% | 2025-09-30 |
| Vanguard Group Inc | $112,971.00 | 7.56% | 18.37M | +2M | +14.58% | 2025-09-30 |
| Janus Henderson Group Plc | $85,018.00 | 5.69% | 13.82M | -1M | -8.19% | 2025-09-30 |
| Macquarie Group Ltd | $64,302.00 | 4.3% | 10.46M | -1M | -8.74% | 2025-09-30 |
| State Street Corp | $59,770.00 | 4% | 9.72M | -123,181 | -1.25% | 2025-09-30 |
| Marshall Wace, Llp | $55,000.00 | 3.68% | 8.94M | -2M | -20.51% | 2025-09-30 |
| Millennium Management Llc | $46,998.00 | 3.15% | 7.64M | -4M | -34.48% | 2025-09-30 |
| Geode Capital Management, Llc | $35,404.00 | 2.37% | 5.76M | +90,698 | +1.6% | 2025-09-30 |
| Nuveen, Llc | $31,826.00 | 2.13% | 5.17M | +2M | +48.28% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $20,375.00 | 1.36% | 3.31M | +854,384 | +34.75% | 2025-09-30 |